Key clinical point: Compared with dupilumab, lebrikizumab in less frequent doses shows equal or improved long-term maintenance of efficacy and overall adverse event rates in patients with moderate-to-severe atopic dermatitis (AD).
Major finding: Between weeks 16 and 52, patients receiving lebrikizumab every 4 weeks (Q4W) vs dupilumab weekly or biweekly (QW/Q2W) were more likely to maintain Investigator’s Global Assessment scores of 0 or 1 (risk ratio [RR] 1.334; P = .035). Lebrikizumab and dupilumab were comparable in terms of adverse event rates (RR 1.052; P = .526) and maintenance of 75% improvement in Eczema Area and Severity Index scores (RR 0.937; P = .490).
Study details: This matching-adjusted indirect comparison study analyzed the data of adult patients with moderate-to-severe AD who received lebrikizumab Q4W (n = 101) in ADvocate1 and ADvocate2 or dupilumab QW/Q2W (n = 169) in SOLO-CONTINUE and achieved a treatment response at week 16.
Disclosures: This study was funded by Almirall S.A., Spain. Two authors declared being employees of Almirall S.A. The other authors declared ties with various sources, including Almirall.
Source: Rand K et al. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of lebrikizumab versus dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2023 (Oct 28). doi: 10.1007/s13555-023-01058-z